**Figure 1. Schematic of glucose oxidase and myeloperoxidase-coupled reactions in E-101 Solution after the addition of glucose substrate.**

**Methods:**

- **Study Drug:** E-101 Solution 100 µL/g, E-101 Solution 300 µL/g, 0.1% sodium lauryl sulfate (positive control) and the 0.9% saline USP negative control applied to abraded and nonabraded human skin. E-101 Solution is a novel antimicrobial agent being developed by Exoxemis, Inc. for direct application within a surgical wound to prevent surgical-site infection.

- **Study Design:** Patient-blinded and evaluator-blinded Phase 1 study.

- **Study Population:** Only participants who met all inclusion criteria (eg, male or female; ≥18 years) in good health without any skin abnormalities on the back and were not rejected by exclusion criteria (eg, pregnant or lactating; use of steroids, antibiotics, or antihyperlipidemic agents; non-participants who were allergic to study agents were enrolled into the study).

- **Study Drugs:** Four study drugs were evaluated: E-101 Solution 300 µL/g, p-MPO 53.7 µg/L, glucose oxidase 8.1 µg/L, 0.1% sodium lauryl sulfate (positive control), 0.9% saline (negative control). Study Drugs: For four study drugs were evaluated: E-101 Solution 300 µL/g, p-MPO 53.7 µg/L, glucose oxidase 8.1 µg/L, 0.1% sodium lauryl sulfate (positive control); 0.9% saline (negative control). Assessments: Each study drug was assessed on abraded and nonabraded skin during 21 consecutive days. Skin testing was performed on 2 test products, 0.1% sodium lauryl sulfate (positive control), and the 0.9% saline USP negative control.

- **Assessments:** Participants were evaluated on abraded and nonabraded skin during 21 consecutive days. Each participant performed skin irritations from 2 test products, positive control, and negative control exposed to E-101 Solution for 21 days. Study Drug: E-101 Solution 300 µL/g administered daily for 21 consecutive days produced mild irritation to abraded and nonabraded skin. However, skin irritation scores were not significantly higher than those of the positive control (p-MPO). Aspergillus niger provides a schematic representation of the reactions occurring in E-101 Solution.